Rituximab

LAUSANNE, Schweiz, July 21, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen die klinische Phase-II-Studie LOTIS-9 zur Untersuchung von ZYNLONTA® (Loncastuximab Tesirine-Lpyl) und…

LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab…

LAUSANNE, Schweiz, July 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute eine freiwillige Unterbrechung der Aufnahme neuer Patienten in die klinische Phase-II-Studie LOTIS-9 (ClinicalTrials.gov-Identifikator:…

Elana Gotkine WEDNESDAY, June 14, 2023 (HealthDay News) -- For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study…

Dr. Reddy’s Laboratories said the studies were for filing in highly regulated markets such as the U.S. and Europe. | Photo Credit: Special Arrangement Drugmaker Dr. Reddy’s Laboratories on Friday said it has successfully completed the full…

ATLANTA -- Patients with newly diagnosed low-burden follicular lymphoma (FL) in remission avoided chemotherapy significantly longer if they received maintenance rituximab (Rituxan)…

A personalized algorithm was developed by researchers in England to recommend retreatment with rituximab (Rituxan) among patients with antineutrophil cytoplasmic antibody…

Patients with rheumatoid arthritis (RA) treated with rituximab (Rituxan) or JAK inhibitors had more severe COVID-19 disease courses, analysis of data from a large registry found. In…

Significantly more patients with moderate-to-severe pemphigus achieved complete remission with rituximab (Rituxan) than with mycophenolate…